Chugai Pharmaceutical Co., Ltd. (CHGCY)
ValueMarkers Composite Index
50% above intrinsic value ($0)
Chugai Pharmaceutical Co., Ltd. (CHGCY) — VMCI valuation read
CHGCY prints VMCI 65/100 inside the Healthcare sector, where the median sits at 50. The 15-point above-median delta is the cleanest single-number summary of Chugai Pharmaceutical Co., Ltd.'s composite stance, and in the mid-cap bucket it places the share ahead of the typical peer on the five-pillar mix.
On CHGCY, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.
**Investor frame.** CHGCY trades at 20.0x earnings, 11% above the Healthcare median of 18.0x; that is the value line. ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of 2.7x is the rate-sensitivity line to watch; that is the risk line for Chugai Pharmaceutical Co., Ltd. on the trailing financials.
CHGCY fell 0.8% over the trailing 7 days, with a -11.9% read on a 30-day basis.
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.